Biomedical Engineering Reference
In-Depth Information
Lilien GL, Weinstein D (1984) An international comparison of the determinants of industrial mar-
keting expenditures. J Market 48(Winter):46-53
Lilien GL, Rao AG, Kalish S (1981) Bayesian estimation and control of detailing effort in a repeat
purchase diffusion environment. Manag Sci 27(5):493-506
Lundy J (2010) Prescription drug trends, Kaiser family foundation fact sheet #3057-08.
http://
www.kff.org
.
Accessed 18 July 2011
Manchanda P, Chintagunta PK (2004) Responsiveness of physician prescription behavior to sales
force effort: an individual level analysis. Mark Lett 15(2-3):129-145
Manchanda P, Honka E (2005) The effects and role of direct-to-physician marketing in the phar-
maceutical industry: an integrative review. Yale J Health Pol Law Ethics 2:785-822
Manchanda P, Rossi PE, Chintagunta PK (2004) Response modeling with nonrandom
marketing-mix variables. J Mark Res 41(4):467-478
the- Pulse-Europe
.
Accessed 20 July 2011
Mantrala MK (2002) Allocating marketing resources. In: Weitz B, Wensley R (eds) Handbook of
marketing. Sage, London, pp 409-435
Mantrala MK, Sinha P, Zoltners AA (1992) Impact of resource allocation rules on marketing
investment-level decisions and profitability. J Mark Res 29(2):162-175
Mitchell LA (1993) An examination of methods of setting advertising budgets: practice and the
literature. Eur J Market 27(5):5-21
Mizik N, Jacobson R (2004) Are physicians 'easy marks'?: quantifying the effects of detailing and
sampling on new prescriptions. Manag Sci 50(12):1704-1715
Montgomery DB, Silk AJ (1972) Estimating dynamic effects of market communications expendi-
tures. Manag Sci 18(10):B485-B501
Montoya R, Netzer O, Jedidi K (2010) Dynamic allocation of pharmaceutical detailing and
sampling for long-term profitability. Mark Sci 29(5):909-924
Nair HS, Manchanda P, Bhatia T (2010) Asymmetric social interactions in physician prescription
behavior: the role of opinion leaders. J Mark Res 47(5):883-895
Narayanan S, Manchanda P (2009) Heterogeneous learning and the targeting of marketing com-
munication for new products. Mark Sci 28(3):424-441
Narayanan S, Desiraju R, Chintagunta PK (2004) Return on investment implications for pharma-
ceutical promotional expenditures: the role of marketing-mix interactions. J Mark 68(4):
90-105
Narayanan S, Manchanda P, Chintagunta PK (2005) Temporal differences in the role of marketing
communication in new product categories. J Mark Res 42(3):278-290
Nerlove M, Arrow KJ (1962) Optimal advertising policy under dynamic conditions. Economica
29(May):129-142
Neslin SA (2001) ROI analysis of pharmaceutical promotion (RAPP): an independent study.
Association of Medical Publications. http://
www.rxpromoroi.org/rapp/
. Accessed 26 Oct 2005
OECD (2011) OECD health data 2011.
http://stats.oecd.org/index.aspx?DataSetCode=HEALTH_
Osinga EC, Leeflang PSH, Wieringa JE (2010) Early marketing matters: a time-varying parameter
approach to persistence modeling. J Mark Res 47(2):173-185
Osinga EC, Leeflang PSH, Srinivasan S, Wieringa JE (2011) Why do firms invest in consumer
advertising with limited sales response? a shareholder perspective. J Mark 75(1):109-124
Parsons LJ, Vanden Abeele P (1981) Analysis of sales call effectiveness. J Mark Res
18(1):107-113
Piercy NF (1987) The marketing budgeting process: marketing management implications.
J Market 51(October):45-59
Prendergast G, West D, Shi Y-Z (2006) Advertising budgeting methods and processes in China.
J Advert 35(3):165-176
Rao AG, Yamada M (1988) Forecasting with a repeat purchase diffusion model. Manag Sci
34(6):734-752
Search WWH ::
Custom Search